Clinical Development Pipeline

Clinical Development Pipeline VideoWe currently have the richest mid-to-late stage pipeline in our history, representing a variety of therapeutic areas including cancer, diabetes, neuroscience and autoimmunity. We’re focused on developing a complementary mix of small and large molecules across our pipeline in order to address the diverse needs of the patients we serve.

For more information on the investigational medicines in our clinical development pipeline, click here.

  • Phase I

    Investigates the safety of a molecule, how it behaves in the human body and possible side effects in a small number of healthy people who do not have the disease.

  • Phase II

    Investigates a molecule's efficacy and short-term side effect profile in a small number of patients who have the disease.

  • Phase III

    Seeks definitive proof of a molecule's efficacy and safety profile in a large number of patients who have the disease.

  • Regulatory Review

    New Drug Application (NDA) is filed with the U.S. Food and Drug Administration (FDA).

  • Select NILEX

    A medicine being investigated to treat a different disease or for which a different formulation is being studied.




The information on this page reflects Eli Lilly and Company's clinical development pipeline. It includes both new molecular entities as well as select new indications or line extensions of currently-approved products, that are currently in clinical development. For competitive reasons, some pipeline molecules are not identified; in those instances, only the therapeutic area in which the molecule is being evaluated is listed.There are significant risks and uncertainties in pharmaceutical research and development. Scientific and regulatory hurdles may cause pipeline molecules to be discontinued, delayed or fail to reach the market. There can be no guarantee that pipeline molecules will receive regulatory approval or that they will prove to be commercially successful. Information on this page is current as of October 19, 2016. Lilly assumes no duty to update this information.

Please enable your browser's JavaScript setting in order to access this site